Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
Year: 2020
Type: review
Abstract: Nonalcoholic fatty liver disease (NAFLD) represents a burgeoning worldwide epidemic whose etiology reflects multiple interactions between environmental and genetic factors. Here, we review the major pathways and dominant genetic modifiers known to be relevant players in human NAFLD and which may determine key components of the heritability of distinctive disease traits including steatosis and fibrosis. In addition, we have employed general assumptions which are based on known genetic factors in NAFLD to build a systems biology prediction model that includes functional enrichment. This prediction model highlights additional complementary pathways that represent plausible intersecting signaling networks that we define here as an NAFLD-Reactome. We review the evidence connecting variants in each of the major known genetic modifiers (variants in patatin-like phospholipase domain containing 3, transmembrane 6 superfamily member 2, membrane-bound O-acyltransferase domain containing 7, glucokinase regulator, and hydroxysteroid 17-beta dehydrogenase 13) to NAFLD and expand the associated underlying mechanisms using functional enrichment predictions, based on both preclinical and cell-based experimental findings. These major candidate gene variants function in distinct pathways, including substrate delivery for de novo lipogenesis; mitochondrial energy use; lipid droplet assembly, lipolytic catabolism, and fatty acid compartmentalization; and very low-density lipoprotein assembly and secretion. The NAFLD-Reactome model expands these pathways and allows for hypothesis testing, as well as serving as a discovery platform for druggable targets across multiple pathways that promote NAFLD development and influence several progressive outcomes. In conclusion, we summarize the strengths and weaknesses of studies implicating selected variants in the pathophysiology of NAFLD and highlight opportunities for future clinical research and pharmacologic intervention, as well as the implications for clinical practice.
Source: Hepatology
DOI: 10.1002/hep.31229
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: European Commission, Consejo Nacional de Investigaciones Científicas y Técnicas, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, National Institutes of Health, Agencia Nacional de Promoción Científica y Tecnológica, National Institute of Diabetes and Digestive and Kidney Diseases, Fondo para la Investigación Científica y Tecnológica
Awards: G1011019262, G153607570, Liver Investigation: Testing Marker Utility in Steatohepatitis, G2262471957, G256965820, G298858806, G360452579, G4011967545, G4092631532, G4101730541, G434337789, G5586110661, G5813863070, Bile acid metabolomics and metagenomics in short bowel syndrome, Acidos nucleicos del microbioma circulantes como biomarcadores de los procesos inflamatorios del Síndrome Metabólico: efecto de la cirugía bariátrica., Cirugia metabólica como novel tratamiento de la diabetes tipo 2: posibles biomarcadores predictores de exito., G6842761660, G6921585545, G7053104719, G7330270157, G7378882120, MECANISMOS ASOCIADOS CON LA PROGRESION DE LA ENFERMEDAD GRASA DEL HIGADO: ANALISIS TRANSCRIPTOMICO HEPATICO, G8090084271, Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans, Diabetes Research Center, Host-environment interactions in the pathophysiology of digestive disease
OpenAlex ID: W3011157697
